cognitive processing: nootropics and compounds | sci-wiki

AC-260584

AC-260584 is an Abbott Laboratories research compound from the 2000s, part of the same M1-muscarinic-agonist wave as sabcomeline and xanomeline but never carried past the tool-compound stage. It was designed as an orally bioavailable, functionally selective M1 agonist that improved cognitive performance in animal testing while sidestepping the receptor subtypes responsible for the GI and cardiac side effects that plagued earlier muscarinic drugs. Unlike some of its contemporaries, AC-260584 does not appear to have been pushed into human trials; its public record is essentially one core pharmacology paper, making it a compound that lives almost entirely in the preclinical literature.

reference

Nootropic

Cerlapirdine

Cerlapirdine was Pfizer's 2010s-era entry into the crowded field of 5-HT6 receptor antagonists chasing Alzheimer's disease, following the same mechanistic bet as idalopirdine and intepirdine: blocking 5-HT6 was thought to indirectly boost cortical acetylcholine and glutamate release and improve cognition. Pfizer ran a Phase II trial specifically in mild-to-moderate Alzheimer's patients who had existing neuropsychiatric symptoms while already stable on donepezil, a narrower bet aimed at the behavioral side of dementia rather than memory alone. The trial, published in 2018, did not separate cerlapirdine from placebo, closing out Pfizer's 5-HT6 program alongside the broader failure of the entire drug class across multiple companies in the same period.

reference

Nootropic

Ispronicline

Ispronicline traces its chemistry back to nicotine research originally funded by tobacco company R.J. Reynolds, which spun off its pharmaceutical research arm into Targacept in the late 1990s. The resulting compound was a partial agonist at alpha4beta2 neuronal nicotinic receptors, designed to capture nicotine's attention- and memory-enhancing effects without its addictive and cardiovascular baggage. AstraZeneca partnered with Targacept and pushed ispronicline (as AZD3480) into a Phase IIb dose-finding trial for mild-to-moderate Alzheimer's disease as well as separate studies for adult ADHD. The Alzheimer's trial, published in 2011, failed to show a robust cognitive benefit, and AstraZeneca discontinued the partnership around 2010-2011, part of a broader collapse of the nicotinic-receptor cognition-enhancement field that also claimed several competing programs.

reference

Nootropic

Milameline

Milameline was Parke-Davis and Roussel-Uclaf's shot at treating Alzheimer's disease by stimulating muscarinic receptors directly instead of propping up acetylcholine with a cholinesterase inhibitor. It is a partial agonist with roughly equal affinity at all five muscarinic subtypes, which was the deliberate choice: no subtype selectivity, just enough intrinsic activity to signal without saturating the system. The preclinical package was strong for its era. It reversed spatial memory deficits in rats with lesioned forebrain cholinergic neurons, raised cortical blood flow, desynchronised the EEG in both rats and rhesus monkeys in the pattern that reads as increased arousal, and rescued scopolamine-impaired attention in monkeys. Then the dose window closed. In Alzheimer's patients, 1 mg every six hours was fine, 2 mg was tolerated by most people, and 2.5 to 3 mg brought sweating, hypersalivation, nausea, diarrhoea, hypotension and, notably, parkinsonian signs including cogwheeling, tremor and a shuffling gait; that study was stopped after the fourth 3 mg dose. The pivotal 52-week trial across 38 centres was then terminated early when an interim analysis projected it would not work. It never worked, and it was never approved.

reference

Nootropic

NGX267

NGX267 started life at Neurogen Corporation and was carried forward by TorreyPines Therapeutics in the mid-to-late 2000s as a dual M1/M4 muscarinic agonist with two proposed uses: improving cognition in Alzheimer's disease and treating xerostomia (severe dry mouth), a side effect common in Sjogren's syndrome and antipsychotic treatment. Its first-in-human dose-escalation study, published in 2009, used an adaptive statistical design that ended up getting cited almost as often for its methodology as for the drug itself. TorreyPines' broader pipeline stalled soon after, the company dissolved and merged into Raptor Pharmaceutical around 2009-2010, and NGX267 was left without a sponsor to carry it into later-phase trials.

reference

Nootropic

Sabcomeline

Sabcomeline was SmithKline Beecham's most clinically advanced muscarinic-agonist candidate for Alzheimer's disease, marketed in development under the name Memric, and it made it further than most of its rivals in this slice, all the way to Phase III. It bound all five muscarinic receptor subtypes with similar raw affinity but showed functional selectivity for M1 in both cell assays and animal behavior, reversing delay-induced memory deficits in marmosets and rats at doses well below those that triggered cholinergic side effects. Despite genuinely promising early signals of symptomatic benefit in Alzheimer's patients without provoking overt cholinergic toxicity, the Phase III program ultimately produced disappointing results and SmithKline Beecham shelved it, one more entry in the long list of muscarinic-agonist Alzheimer's drugs that looked good on paper and in monkeys but not in a pivotal trial.

reference